Fertility and Sterility
Volume 78, Issue 5 , Pages 1068-1072 , November 2002

Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist

  • Shaun C Williams, M.D.

      Affiliations

    • Jones Institute for Reproductive Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia, USA
    • Corresponding Author InformationReprint requests: Shaun C. Williams, M.D., The Jones Institute for Reproductive Medicine, 601 Colley Avenue, Norfolk, Virginia 23507, USA (FAX: 757-446-8998)
  • ,
  • William E Gibbons, M.D.

      Affiliations

    • Jones Institute for Reproductive Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia, USA
  • ,
  • Suheil J Muasher, M.D.

      Affiliations

    • Jones Institute for Reproductive Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia, USA
  • ,
  • Sergio Oehninger, M.D.

      Affiliations

    • Jones Institute for Reproductive Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia, USA

Received 11 November 2000

References 

  1. Liu HC, Lai YM, Davis O, Berkeley AS, Graf M, Griffo J, et al.  Improved pregnancy outcome with gonadotropin releasing hormone agonist stimulation is due to the improvement in oocyte quantity rather than quality. J Assist Reprod Genet. 1992;9:338–344
  2. Droesch K, Muasher SJ, Brzyski RG, Jones GS, Simonetti S, Liu HC, et al.  Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization. Fertil Steril. 1989;52:518–519
  3. Diamond MP, Hill GA, Webster BW, Herbert CM, Rogers BJ, Osteen KG, et al.  Comparison of human menopausal gonadotropin, clomiphene citrate, and combined human menopausal gonadotropin-clomiphene citrate stimulation protocols for in vitro fertilization. Fertil Steril. 1986;46:1108–1112
  4. Tummen IS, Daniel SAJ, Kaplan BR, Nisker JA, Yuzpe AA. Randomized, prospective comparison of luteal leuprolide acetate and gonadotropins versus clomiphene citrate and gonadotropins in 408 first cycles of in vitro fertilization. Fertil Steril. 1992;58:563–568
  5. Benadiva CA, Davis O, Kligman I, Liu HC, Rosenwaks Z. Clomiphene citrate and hMG (an alternative stimulation protocol for selected failed in vitro fertilization patients). J Assist Reprod Genet. 1995;12:8–12
  6. Corfman RS, Milad MP, Bellavance TL, Ory SJ, Erickson LD, Ball GD. A novel ovarian stimulation protocol for use with the assisted reproductive technologies. Fertil Steril. 1993;60:864–870
  7. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril. 1989;51:651–654
  8. Droesch K, Muasher SJ, Kreiner D, Jones GS, Acosta AA, Rosenwaks Z. Timing of oocyte retrieval in cycles with a spontaneous luteinizing hormone surge in a large in vitro fertilization program. Fertil Steril. 1998;50:451–456
  9. Toner JP, Brzyski RG, Oehninger S, Veeck LL, Simonetti S, Muasher SJ. Combined impact of the number of pre-ovulatory oocytes and cryopreservation on IVF outcome. Hum Reprod. 1991;6:284–289
  10. European Orgalutran Study Group Borm G, Mannaerts B. Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe, and convenient (results of a controlled, randomized, multicenter trial). Hum Reprod. 2000;15:1490–1498
  11. Rongieres-Bertrand C, Olivennes F, Righini C, Fanchin R, Taieb J, Hamamah S, et al.  Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix) (a pilot study with minimal stimulation). Hum Reprod. 1999;14:683–688

PII: S0015-0282(02)03374-5

Fertility and Sterility
Volume 78, Issue 5 , Pages 1068-1072 , November 2002